Programmed death ligand 1 (PD-L1) is expressed in 21–75% of ccRCC tumors, and allows cancer cells to evade immune response [34,35,36,37,38,39,40,41,42,43,44,45,46,47]. This evidence concerns the gene CD274 and nonpapillary renal cell carcinoma.